New York: November 21, 2024

The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in New York City, on 21 November, to discuss collaborative solutions that can help achieve better health outcomes globally, and how the scientific and medical innovation delivered by the pharmaceutical industry can have a positive societal and economic impact.

Athens: April 3-4, 2024

The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in April, Greece, on 3 and 4 April 2024, to discuss global health challenges and public health policies impacting biomedical innovation.

A delegation of CEOs met with Greek Prime Minister Kyriakos Mitsotakis and other officials to discuss shared priorities, focused on lessons learned in driving research and development to address the COVID-19 pandemic, and the importance of supporting innovation and ensuring patient access to medicines.

New York: November 28, 2023

The Biopharmaceutical CEO Roundtable (BCR) met in New York on 28 November 2023 to focus on global health challenges and the importance of pharmaceutical innovation to the health and economic security of countries around the world. The meeting included discussion on how the industry can use its expertise to address the biggest global health challenges and achieve health equity. Fostering a sustainable global innovation ecosystem supported by the intellectual property framework emerged as a key focal point during discussions.

Tokyo: April 13-14, 2023

CEOs met with officials from met with Japanese Prime Minister Fumio Kishida and other officials. They praised Japan’s efforts in promoting innovation to address future pandemics, Universal Health Coverage goals, and combat antimicrobial resistance. The meeting took place a month before Japan hosts the G7 Hiroshima Summit. The CEOs presented the Tokyo Statement of the BCR to PM Kishida, which outlined top priorities for addressing global health challenges. They also discussed the importance to strengthen the innovation ecosystem in Japan and proposed establishing a strategic dialogue platform to enhance Japan’s leadership position in the life science sector by fostering innovation that benefits both patients and economic growth.

Madrid: December 21, 2022

The Spanish Prime Minister, Pedro Sánchez, and the Ministers of Industry, Trade and Tourism, Reyes Maroto; Health, Carolina Darias; and Science and Innovation, Diana Morant, held a meeting on 21  December 2022 with over 20 presidents and top executives of pharmaceutical companies at global and national level, as well as with representatives of the sector’s trade associations, including IFPMA Director General Thomas Cueni and EFPIA Director General Nathalie Moll, with the objective of laying the foundations for a Strategic Plan to promote the development of the innovation pharmaceutical industry in Spain.

Berlin: June 20-21, 2022

CEOs met with officials from the German ministries of health and economic development as well as the Federal Chancellor’s office to discuss national and international developments that impact future innovation and global health.

They also discussed how the German government and industry can work together to reinvigorate innovation across the life sciences ecosystem.

London (virtual): December 2, 2021

CEOs met with the Prime Minister, senior UK Cabinet Ministers, and the NHS Chief Executive to discuss global health and innovation.

Discussions focused on how the industry and UK Government can work together to drive pharmaceutical innovation, rapidly deliver the next generation of medicines to patients worldwide and realize the UK Government’s Life Sciences Vision.

Brussels: June 21-22, 2021

CEOs discussed global health challenges and public health policies impacting biomedical innovation.

Tokyo: June 3-4, 2019

CEOs from IFPMA, Pharmaceutical Researchers and Manufacturers of America (PhRMA), the Japan Pharmaceutical Association (JPMA), and the European Federation of Pharmaceutical Industries and Associations (EFPIA) handed a joint statement to Japanese Prime Minister Shinzo Abe.

It called for Japan to:

• Accelerate efforts around universal health coverage, especially in developing countries
• Support development in areas with no effective treatments, such as antimicrobial treatments, through partnerships, regulatory harmonization, and predictable and reasonable IP protection rules
• Craft legal frameworks that facilitate the use of AI and big data.

PM Abe expressed the Japanese government’s resolve to promote innovation.